ClinicalTrials.gg
CompletedNCT00644735Updated Mar 26, 2009

Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed

A Phase 4 interventional study of Esomeprazole and Lansoprazole in Erosive Esophagitis, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-03-26.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing esomeprazole in Heartburn — none open to participants now, none under way, none of them phase 3. Esomeprazole · Heartburn.

Planned enrollment
3rd of 19
750 · median 248
Started
2002
with 2 others
Phase 4
15 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
15 of 19
AstraZeneca

Among the 19 studies testing esomeprazole in Heartburn, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2002, is one of 15 in phase 4, and was the 11th registered.

Heartburn

154 studies on the registry are indexed under Heartburn; 12 are open to participants now.

Browse Heartburn studies →

Open to participants now

None of the 19 studies testing esomeprazole in Heartburn is open now. The open studies under Heartburn, anywhere →

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing esomeprazole in Heartburn as a file.
02

Study summary

A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

Keywords

  • Erosive Esophagitis
  • Nexium
  • Esomeprazole
  • Lansoprazole
  • Heartburn
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Episodes of heartburn (described as a burning feeling rising from the stomach or lower part of the chest up towards the neck) for 2 days or more during the last 7 days prior to baseline
  • Confirmed diagnosis of Erosive Esophagus, patients must undergo an endoscopy before entering the study.

Exclusion criteria

Exclusion Criteria:

  • Any signs of gastrointestinal bleeding at the time of the starting the study.
  • Any previous gastric or esophageal surgery.
  • Various gastrointestinal diseases as listed in the protocol.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    1

    Nexium

    Drug: Esomeprazole

  • Active comparator
    2

    Prevacid

    Drug: Lansoprazole

Interventions

06

What researchers measure

Primary outcomes

  1. To compare rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).

    Time frame: Symptoms will be assessed by the investigator at each visit and the patients will undergo an endoscopy at Months 3 and 6

Secondary outcomes

  1. To compare endoscopic remission rates through 6 months of treatment with E20 and L15, after initial healing of EE.

    Time frame: Symptoms will be assessed by the investigator at each visit and the patients will undergo an endoscopy at Months 3 and 6

  2. The assessment of symptoms in the two treatment groups after 1, 3 and 6 months.

    Time frame: patients will undergo an endoscopy at Months 3 and 6

  3. To assess the safety and tolerability of up to 6 months of treatment with E20 and L15 after initial healing of EE.

    Time frame: Symptoms will be assessed by the investigator at each visit and the patients will undergo an endoscopy at Months 3 and 6

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Jan 2004 and a completion of Jan 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 27, 2008
Start
Dec 2002
Primary completionActual
Jan 2004
CompletionActual
Jan 2004
Last update
Mar 26, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00644735
Lead sponsor
AstraZeneca
First posted
Mar 27, 2008
Start date
Dec 2002
Primary completion
Jan 2004
Completion
Jan 2004
Last update
Mar 26, 2009

Study contacts

Paula Fernstrom
study director · Nexium Global Product Director, AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion